Jeffrey L Dage1, Alexandra M V Wennberg2, David C Airey1, Clinton E Hagen3, David S Knopman4, Mary M Machulda5, Rosebud O Roberts6, Clifford R Jack7, Ronald C Petersen4, Michelle M Mielke8. 1. Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA. 2. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 3. Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 4. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 5. Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA. 6. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA. 7. Department of Radiology, Mayo Clinic, Rochester, MN, USA. 8. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; Department of Neurology, Mayo Clinic, Rochester, MN, USA. Electronic address: mielke.michelle@mayo.edu.
Abstract
INTRODUCTION: Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)-related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. METHODS: Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1 tau assay. RESULTS: Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = -0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). DISCUSSION: Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.
INTRODUCTION:Tau protein levels in plasma may be a marker of neuronal damage. We examined associations between plasma tau levels and Alzheimer's disease (AD)-related magnetic resonance imaging (MRI) and positron emission tomography (PET) neuroimaging measures among nondemented individuals. METHODS:Participants included 378 cognitively normal (CN) and 161 mild cognitive impairment (MCI) individuals enrolled in the Mayo Clinic Study of Aging with concurrent neuropsychological measures and amyloid PET, fluorodeoxyglucose PET, and MRI. Baseline plasma tau levels were measured using the Quanterix Simoa-HD1tau assay. RESULTS: Plasma tau levels were higher in MCI compared with CN (4.34 vs. 4.14 pg/mL, P = .078). In regression models adjusted for age, gender, education, and APOE, higher plasma tau was associated with worse memory performance (b = -0.30, P = .02) and abnormal cortical thickness in an AD signature region (odds ratio = 1.80, P = .018). DISCUSSION: Plasma tau is associated with cortical thickness and memory performance. Longitudinal studies will better elucidate the associations between plasma tau, neurodegeneration, and cognition.
Authors: Susan M Landau; Danielle Harvey; Cindee M Madison; Robert A Koeppe; Eric M Reiman; Norman L Foster; Michael W Weiner; William J Jagust Journal: Neurobiol Aging Date: 2009-08-05 Impact factor: 4.673
Authors: Selam Negash; Glenn E Smith; Shane Pankratz; Jeremiah Aakre; Yonas E Geda; Rosebud O Roberts; David S Knopman; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen Journal: Am J Geriatr Psychiatry Date: 2011-06 Impact factor: 4.105
Authors: Jeffrey Randall; Erik Mörtberg; Gail K Provuncher; David R Fournier; David C Duffy; Sten Rubertsson; Kaj Blennow; Henrik Zetterberg; David H Wilson Journal: Resuscitation Date: 2012-08-09 Impact factor: 5.262
Authors: Clifford R Jack; David S Knopman; Stephen D Weigand; Heather J Wiste; Prashanthi Vemuri; Val Lowe; Kejal Kantarci; Jeffrey L Gunter; Matthew L Senjem; Robert J Ivnik; Rosebud O Roberts; Walter A Rocca; Bradley F Boeve; Ronald C Petersen Journal: Ann Neurol Date: 2012-04-09 Impact factor: 10.422
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Yi Su; Tyler M Blazey; Abraham Z Snyder; Marcus E Raichle; Daniel S Marcus; Beau M Ances; Randall J Bateman; Nigel J Cairns; Patricia Aldea; Lisa Cash; Jon J Christensen; Karl Friedrichsen; Russ C Hornbeck; Angela M Farrar; Christopher J Owen; Richard Mayeux; Adam M Brickman; William Klunk; Julie C Price; Paul M Thompson; Bernadino Ghetti; Andrew J Saykin; Reisa A Sperling; Keith A Johnson; Peter R Schofield; Virginia Buckles; John C Morris; Tammie L S Benzinger Journal: Neuroimage Date: 2014-12-05 Impact factor: 6.556
Authors: Val J Lowe; Bradley J Kemp; Clifford R Jack; Matthew Senjem; Stephen Weigand; Maria Shiung; Glenn Smith; David Knopman; Bradley Boeve; Brian Mullan; Ronald C Petersen Journal: J Nucl Med Date: 2009-05-14 Impact factor: 10.057
Authors: Jere E Meredith; Sethu Sankaranarayanan; Valerie Guss; Anthony J Lanzetti; Flora Berisha; Robert J Neely; J Randall Slemmon; Erik Portelius; Henrik Zetterberg; Kaj Blennow; Holly Soares; Michael Ahlijanian; Charles F Albright Journal: PLoS One Date: 2013-10-07 Impact factor: 3.240
Authors: Michelle M Mielke; Clinton E Hagen; Jing Xu; Xiyun Chai; Prashanthi Vemuri; Val J Lowe; David C Airey; David S Knopman; Rosebud O Roberts; Mary M Machulda; Clifford R Jack; Ronald C Petersen; Jeffrey L Dage Journal: Alzheimers Dement Date: 2018-04-05 Impact factor: 21.566
Authors: Sid E O'Bryant; Michelle M Mielke; Robert A Rissman; Simone Lista; Hugo Vanderstichele; Henrik Zetterberg; Piotr Lewczuk; Holly Posner; James Hall; Leigh Johnson; Yiu-Lian Fong; Johan Luthman; Andreas Jeromin; Richard Batrla-Utermann; Alcibiades Villarreal; Gabrielle Britton; Peter J Snyder; Kim Henriksen; Paula Grammas; Veer Gupta; Ralph Martins; Harald Hampel Journal: Alzheimers Dement Date: 2016-11-18 Impact factor: 21.566
Authors: Zhicheng Chen; David Mengel; Ashvini Keshavan; Robert A Rissman; Andrew Billinton; Michael Perkinton; Jennifer Percival-Alwyn; Aaron Schultz; Michael Properzi; Keith Johnson; Dennis J Selkoe; Reisa A Sperling; Purvish Patel; Henrik Zetterberg; Douglas Galasko; Jonathan M Schott; Dominic M Walsh Journal: Alzheimers Dement Date: 2018-11-09 Impact factor: 21.566
Authors: Michelle M Mielke; Clinton E Hagen; Alexandra M V Wennberg; David C Airey; Rodolfo Savica; David S Knopman; Mary M Machulda; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Jeffrey L Dage Journal: JAMA Neurol Date: 2017-09-01 Impact factor: 18.302
Authors: Kacie D Deters; Shannon L Risacher; Sungeun Kim; Kwangsik Nho; John D West; Kaj Blennow; Henrik Zetterberg; Leslie M Shaw; John Q Trojanowski; Michael W Weiner; Andrew J Saykin Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472